

Chan Yoon Cheah

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1431371/publications.pdf>

Version: 2024-02-01

113
papers

3,639
citations

201385

27
h-index

143772

57
g-index

113
all docs

113
docs citations

113
times ranked

4198
citing authors

#	ARTICLE	IF	CITATIONS
1	Breast Implantâ€Associated Anaplastic Large-Cell Lymphoma: Long-Term Follow-Up of 60 Patients. <i>Journal of Clinical Oncology</i> , 2014, 32, 114-120.	0.8	338
2	Bacterial Biofilm Infection Detected in Breast Implantâ€Associated Anaplastic Large-Cell Lymphoma. <i>Plastic and Reconstructive Surgery</i> , 2016, 137, 1659-1669.	0.7	286
3	Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study. <i>Lancet, The</i> , 2021, 397, 892-901.	6.3	260
4	Mantle Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2016, 34, 1256-1269.	0.8	247
5	Primary testicular lymphoma. <i>Blood</i> , 2014, 123, 486-493.	0.6	166
6	Mosunetuzumab Induces Complete Remissions in Poor Prognosis Non-Hodgkin Lymphoma Patients, Including Those Who Are Resistant to or Relapsing After Chimeric Antigen Receptor T-Cell (CAR-T) Therapies, and Is Active in Treatment through Multiple Lines. <i>Blood</i> , 2019, 134, 6-6.	0.6	152
7	Idelalisib in the management of lymphoma. <i>Blood</i> , 2016, 128, 331-336.	0.6	120
8	Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study. <i>Lancet Oncology, The</i> , 2022, 23, 1055-1065.	5.1	119
9	Patients with myeloid malignancies bearing PDGFRB fusion genes achieve durable long-term remissions with imatinib. <i>Blood</i> , 2014, 123, 3574-3577.	0.6	118
10	Umbralisib, a Dual PI3KÎ/CK1Î Inhibitor in Patients With Relapsed or Refractory Indolent Lymphoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 1609-1618.	0.8	111
11	Primary breast lymphoma. <i>Cancer Treatment Reviews</i> , 2014, 40, 900-908.	3.4	109
12	Treatment strategies, outcomes and prognostic factors in 291 patients with secondary CNS involvement by diffuse large B-cell lymphoma. <i>European Journal of Cancer</i> , 2018, 93, 57-68.	1.3	90
13	Lenalidomide, idelalisib, and rituximab are unacceptably toxic in patients with relapsed/refractory indolent lymphoma. <i>Blood</i> , 2015, 125, 3357-3359.	0.6	87
14	Rituximab plus hyperâ€CVAD</sc> alternating with <sc>MTX</sc>/Araâ€ in patients with newly diagnosed mantle cell lymphoma: 15â€year followâ€up of a phase <sc>II</sc> study from the <sc>MD</sc> Anderson Cancer Center. <i>British Journal of Haematology</i> , 2016, 172, 80-88.	1.2	82
15	Role of the tumor microenvironment in mature B-cell lymphoid malignancies. <i>Haematologica</i> , 2016, 101, 531-540.	1.7	75
16	The number of extranodal sites assessed by PET/CT scan is a powerful predictor of CNS relapse for patients with diffuse large B-cell lymphoma: An international multicenter study of 1532 patients treated with chemoimmunotherapy. <i>European Journal of Cancer</i> , 2017, 75, 195-203.	1.3	65
17	Encouraging activity for R-CHOP in advanced stage nodular lymphocyteâ€predominant Hodgkin lymphoma. <i>Blood</i> , 2017, 130, 472-477.	0.6	65
18	A clinician's guide to double hit lymphomas. <i>British Journal of Haematology</i> , 2015, 168, 784-795.	1.2	54

#	ARTICLE	IF	CITATIONS
19	Mosunetuzumab Shows Promising Efficacy in Patients with Multiply Relapsed Follicular Lymphoma: Updated Clinical Experience from a Phase I Dose-Escalation Trial. <i>Blood</i> , 2020, 136, 42-44.	0.6	44
20	Timing of high-dose methotrexate CNS prophylaxis in DLBCL: a multicenter international analysis of 1384 patients. <i>Blood</i> , 2022, 139, 2499-2511.	0.6	42
21	COO and MYC/BCL2 status do not predict outcome among patients with stage I/II DLBCL: a retrospective multicenter study. <i>Blood Advances</i> , 2019, 3, 2013-2021.	2.5	40
22	Australian and New Zealand consensus statement on the management of lymphoma, chronic lymphocytic leukaemia and myeloma during the COVID-19 pandemic. <i>Internal Medicine Journal</i> , 2020, 50, 667-679.	0.5	37
23	Burkitt Lymphoma International Prognostic Index. <i>Journal of Clinical Oncology</i> , 2021, 39, 1129-1138.	0.8	37
24	Dulanermin with rituximab in patients with relapsed indolent B-cell lymphoma: an open-label phase 1b/2 randomised study. <i>Lancet Haematology</i> , 2015, 2, e166-e174.	2.2	36
25	Uterine, but not ovarian, female reproductive organ involvement at presentation by diffuse large B-cell lymphoma is associated with poor outcomes and a high frequency of secondary CNS involvement. <i>British Journal of Haematology</i> , 2016, 175, 876-883.	1.2	34
26	BTK Leu528Trp - a Potential Secondary Resistance Mechanism Specific for Patients with Chronic Lymphocytic Leukemia Treated with the Next Generation BTK Inhibitor Zanubrutinib. <i>Blood</i> , 2019, 134, 170-170.	0.6	33
27	Ibrutinib for central nervous system lymphoma: the Australasian Lymphoma Alliance/MD Anderson Cancer Center experience. <i>British Journal of Haematology</i> , 2021, 192, 1049-1053.	1.2	31
28	Non-Covalent BTK Inhibitors – The New BTKids on the Block for B-Cell Malignancies. <i>Journal of Personalized Medicine</i> , 2021, 11, 764.	1.1	30
29	Rasburicase Causing Severe Oxidative Hemolysis and Methemoglobinemia in a Patient with Previously Unrecognized Glucose-6-Phosphate Dehydrogenase Deficiency. <i>Acta Haematologica</i> , 2013, 130, 254-259.	0.7	27
30	Therapeutic options for relapsed/refractory mantle cell lymphoma. <i>Blood</i> , 2022, 139, 666-677.	0.6	27
31	Impact of histologic subtypes and treatment modality among patients with primary central nervous system lymphoma: a SEER database analysis. <i>Oncotarget</i> , 2018, 9, 28897-28902.	0.8	26
32	Fluoroquinolone-induced immune thrombocytopenia: a report and review. <i>Internal Medicine Journal</i> , 2009, 39, 619-623.	0.5	25
33	Intensive chemoimmunotherapy and bilateral globe irradiation as initial therapy for primary intraocular lymphoma. <i>Neuro-Oncology</i> , 2016, 18, 575-581.	0.6	24
34	How I treat patients with aggressive lymphoma at high risk of CNS relapse. <i>Blood</i> , 2017, 130, 867-874.	0.6	24
35	Impact of R-CHOP dose intensity on survival outcomes in diffuse large B-cell lymphoma: a systematic review. <i>Blood Advances</i> , 2021, 5, 2426-2437.	2.5	24
36	IgG4-related disease with cutaneous manifestations treated with rituximab: Case report and literature review. <i>Australasian Journal of Dermatology</i> , 2014, 55, 132-136.	0.4	23

#	ARTICLE	IF	CITATIONS
37	Subcutaneous Mosunetuzumab in Relapsed or Refractory B-Cell Lymphoma: Promising Safety and Encouraging Efficacy in Dose Escalation Cohorts. <i>Blood</i> , 2020, 136, 45-46.	0.6	22
38	Marginal zone lymphoma: present status and future perspectives. <i>Haematologica</i> , 2022, 107, 35-43.	1.7	22
39	Ibrutinib improves survival compared with chemotherapy in mantle cell lymphoma with central nervous system relapse. <i>Blood</i> , 2022, 140, 1907-1916.	0.6	22
40	Central Nervous System Prophylaxis in Non-Hodgkin Lymphoma: Who, What, and When?. <i>Current Oncology Reports</i> , 2015, 17, 25.	1.8	19
41	Novel agents for relapsed and refractory follicular lymphoma. <i>Best Practice and Research in Clinical Haematology</i> , 2018, 31, 41-48.	0.7	19
42	Comprehensive geriatric assessment is useful in an elderly Australian population with diffuse large B-cell lymphoma receiving rituximab-chemotherapy combinations. <i>British Journal of Haematology</i> , 2019, 187, 73-81.	1.2	19
43	Targeting the programmed death-1/programmed death-ligand 1 axis in lymphoma. <i>Current Opinion in Oncology</i> , 2015, 27, 384-391.	1.1	18
44	An international multicenter retrospective analysis of patients with extranodal marginal zone lymphoma and histologically confirmed central nervous system and dural involvement. <i>Cancer Medicine</i> , 2020, 9, 663-670.	1.3	17
45	Mirtazapine associated with profound hyponatremia: Two case reports. <i>American Journal of Geriatric Pharmacotherapy</i> , 2008, 6, 91-95.	3.0	16
46	Stage I Non-Hodgkin Lymphoma: difference in survival outcome by primary extranodal site of involvement. <i>British Journal of Haematology</i> , 2019, 185, 334-338.	1.2	16
47	LOXO-305, A Next Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated CLL/SLL: Results from the Phase 1/2 BRUIN Study. <i>Blood</i> , 2020, 136, 35-37.	0.6	16
48	Clinical characteristics and outcomes of patients with Hodgkin lymphoma with central nervous system involvement: An international multicenter collaboration. <i>American Journal of Hematology</i> , 2016, 91, 894-899.	2.0	15
49	Outcomes of stage I/II follicular lymphoma in the PET era: an international study from the Australian Lymphoma Alliance. <i>Blood Advances</i> , 2019, 3, 2804-2811.	2.5	15
50	High-Dose Methotrexate Is Not Associated with Reduction in CNS Relapse in Patients with Aggressive B-Cell Lymphoma: An International Retrospective Study of 2300 High-Risk Patients. <i>Blood</i> , 2021, 138, 181-181.	0.6	14
51	New Directions for Mantle Cell Lymphoma in 2022. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2022, 42, 614-628.	1.8	14
52	Integrated safety analysis of umbralisib, a dual PI3K δ /CK1 β inhibitor, in relapsed/refractory lymphoid malignancies. <i>Blood Advances</i> , 2021, 5, 5332-5343.	2.5	13
53	Fibrinogen Melbourne. <i>Blood Coagulation and Fibrinolysis</i> , 2012, 23, 563-565.	0.5	12
54	Favorable outcomes with de-escalated radiation therapy for limited-stage nodular lymphocyte-predominant Hodgkin lymphoma. <i>Blood Advances</i> , 2019, 3, 1356-1367.	2.5	12

#	ARTICLE	IF	CITATIONS
55	Minimal relapse risk and early normalization of survival for patients with Burkitt lymphoma treated with intensive immunochemotherapy: an international study of 264 real-world patients. <i>British Journal of Haematology</i> , 2020, 189, 661-671.	1.2	12
56	Stage I non-Hodgkin lymphoma: no plateau in disease-specific survival?. <i>Annals of Hematology</i> , 2019, 98, 1169-1176.	0.8	11
57	Recognizing Unmet Need in the Era of Targeted Therapy for CLL/SLL: "What's Past Is Prologue" (Shakespeare). <i>Clinical Cancer Research</i> , 2022, 28, 603-608.	3.2	11
58	Pre-treatment total metabolic tumour volumes in lymphoma: Does quantity matter?. <i>British Journal of Haematology</i> , 2022, 197, 139-155.	1.2	11
59	When to treat patients with relapsed follicular lymphoma. <i>Expert Review of Hematology</i> , 2017, 10, 187-191.	1.0	10
60	Secondary haemophagocytic lymphohistiocytosis due to checkpoint inhibitor therapy. <i>European Journal of Cancer</i> , 2019, 115, 84-87.	1.3	10
61	High-dose therapy and autologous stem cell transplantation may only be applicable to selected patients with secondary CNS diffuse large B-cell lymphoma. <i>British Journal of Haematology</i> , 2017, 178, 991-994.	1.2	9
62	The diagnostic and therapeutic challenges of Grade 3B follicular lymphoma. <i>British Journal of Haematology</i> , 2021, 195, 15-24.	1.2	9
63	Thrombotic thrombocytopenic purpura in a patient with lenalidomide-responsive multiple myeloma. <i>Annals of Hematology</i> , 2015, 94, 1605-1607.	0.8	8
64	Frontline management of indolent non-Hodgkin lymphoma in Australia. Part 2: mantle cell lymphoma and marginal zone lymphoma. <i>Internal Medicine Journal</i> , 2019, 49, 1070-1080.	0.5	8
65	Umbralisib, the Once Daily Dual Inhibitor of PI3K and Casein Kinase-1 μ Demonstrates Clinical Activity in Patients with Relapsed or Refractory Indolent Non-Hodgkin Lymphoma: Results from the Phase 2 Global Unity-NHL Trial. <i>Blood</i> , 2020, 136, 34-35.	0.6	8
66	Pirtobrutinib, A Next Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated Mantle Cell Lymphoma: Updated Results from the Phase 1/2 BRUIN Study. <i>Blood</i> , 2021, 138, 381-381.	0.6	8
67	Pirtobrutinib, A Next Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated CLL/SLL: Updated Results from the Phase 1/2 BRUIN Study. <i>Blood</i> , 2021, 138, 391-391.	0.6	8
68	Premature closure of a phase II study of bendamustine, mitoxantrone and rituximab for patients with untreated high-risk follicular lymphoma due to severe haematological and infectious toxicity. <i>British Journal of Haematology</i> , 2016, 175, 531-533.	1.2	7
69	Peripheral T-Cell Lymphoma Arising in Patients With Chronic Lymphocytic Leukemia. <i>American Journal of Clinical Pathology</i> , 2019, 152, 818-827.	0.4	7
70	Real world data as a key element in precision medicine for lymphoid malignancies: potentials and pitfalls. <i>British Journal of Haematology</i> , 2019, 186, 409-419.	1.2	7
71	Detection of Del(17p) in Hematological Malignancies By Imaging Flow Cytometry. <i>Blood</i> , 2020, 136, 9-10.	0.6	7
72	11q23 rearrangement and duplication of MLLT1 gene fusion in therapy-related acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2012, 53, 2066-2068.	0.6	6

#	ARTICLE	IF	CITATIONS
73	Dose-reduced fludarabine, cyclophosphamide and rituximab is well tolerated in older patients with chronic lymphocytic leukemia and has preserved therapeutic efficacy. <i>Leukemia and Lymphoma</i> , 2016, 57, 1044-1053.	0.6	5
74	A multicenter retrospective comparison of induction chemoimmunotherapy regimens on outcomes in transplant-eligible patients with previously untreated mantle cell lymphoma. <i>Hematological Oncology</i> , 2019, 37, 253-260.	0.8	5
75	Front-line management of non-Hodgkin lymphoma in Australia. Part 1: follicular lymphoma. <i>Internal Medicine Journal</i> , 2019, 49, 422-433.	0.5	5
76	LOXO-305, A Next Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated Mantle Cell Lymphoma, Waldenström's Macroglobulinemia, and Other Non-Hodgkin Lymphomas: Results from the Phase 1/2 BRUIN Study. <i>Blood</i> , 2020, 136, 8-10.	0.6	5
77	Comment on "Drug-Induced Thrombocytopenia: An Updated Systematic Review". <i>Drug Safety</i> , 2009, 32, 707.	1.4	4
78	Diffuse large B-cell lymphoma with microsatellite instability developing in the setting of Muir-Torre variant hereditary non-polyposis colon cancer. <i>Journal of Clinical Pathology</i> , 2015, 68, 755-757.	1.0	4
79	Refractory $\hat{\pm}/\hat{\pm}^2$ -Hepatosplenic T-cell Lymphoma With Secondary CNS Dissemination and Severe Morbidity Related to Intrathecal Chemotherapy: A Case Report and Literature Review. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e564-e567.	0.2	4
80	Incorporating High-Dose IV Methotrexate Into Initial Therapy Results In Lower Rates Of Central Nervous System (CNS) Relapse In Patients With High-Risk Diffuse Large B-Cell Lymphoma (DLBCL). <i>Blood</i> , 2013, 122, 4353-4353.	0.6	4
81	The Selective Bruton Tyrosine Kinase (BTK) Inhibitor TG-1701 As Monotherapy and in Combination with Ublituximab and Umbralisib (U2) in Patients with B-Cell Malignancies. <i>Blood</i> , 2021, 138, 1549-1549.	0.6	4
82	Rituximab for the treatment of follicular lymphoma. <i>Future Oncology</i> , 2013, 9, 1283-1298.	1.1	3
83	Complete remission following lenalidomide and rituximab in a patient with heavily pretreated nodular lymphocyte predominant Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2016, 57, 1974-1976.	0.6	3
84	An Individualized Risk Mitigation Approach for Safety: Experience from the Mosunetuzumab (CD20/CD3) Tj ETQq0 0 0 rgBT /Overlock 1 4728-4728.	0.6	3
85	Management and Outcomes of Diffuse Large B-cell Lymphoma Post-transplant Lymphoproliferative Disorder in the Era of PET and Rituximab: A Multicenter Study From the Australasian Lymphoma Alliance. <i>HemaSphere</i> , 2021, 5, e648.	1.2	3
86	Normalization of Survival and No Relapses after One Year in Adult Burkitt Lymphoma Patients Treated with Intensive Immunochemotherapy: An International Study of 159 Real-World Patients. <i>Blood</i> , 2018, 132, 452-452.	0.6	3
87	Refining the predictors of risk for central nervous system involvement in patients with mantle cell lymphoma. <i>Leukemia and Lymphoma</i> , 2013, 54, 1859-1861.	0.6	2
88	Synchronous biphenotypic Richter syndrome with Epstein-Barr virus-positive nodal classical Hodgkin lymphoma and bone marrow diffuse large B-cell lymphoma. <i>Histopathology</i> , 2016, 69, 707-710.	1.6	2
89	An International Collaborative Study of Outcome and Prognostic Factors in Patients with Secondary CNS Involvement By Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2016, 128, 1874-1874.	0.6	2
90	Primary Testicular Lymphoma. , 2017, , 129-141.		2

#	ARTICLE	IF	CITATIONS
91	Ongoing challenge of optimal patient selection for CNS prophylaxis in patients with non-Hodgkin lymphoma. <i>International Journal of Hematologic Oncology</i> , 2014, 3, 189-201.	0.7	1
92	Novel Treatments for T-Cell Lymphoma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2015, , e468-e478.	1.8	1
93	Acute and late toxicity of bilateral orbital irradiation in the management of primary intraocular lymphoma. <i>Leukemia and Lymphoma</i> , 2016, 57, 2612-2618.	0.6	1
94	The Diagnostic, Prognostic, and Therapeutic Utility of Molecular Testing in a Patient with Waldenstrom's Macroglobulinemia. <i>International Journal of Molecular Sciences</i> , 2017, 18, 2038.	1.8	1
95	Characteristics and outcome of patients with relapsed/refractory Hodgkin lymphoma following front-line escalated BEACOPP-based chemotherapy: a report from the Australasian Lymphoma Alliance. <i>Leukemia and Lymphoma</i> , 2020, 61, 3412-3416.	0.6	1
96	Simultaneous intraocular and cutaneous extranodal NK/T-cell lymphoma refractory to multiple therapies including pembrolizumab. <i>Clinical Case Reports (discontinued)</i> , 2021, 9, e04194.	0.2	1
97	Event-Free and Overall Survival in over 6,000 Patients Treated with Frontline Immunochemotherapy for Follicular Lymphoma between 2002-2018: First Report from the International FLIPI24 Consortium. <i>Blood</i> , 2021, 138, 3527-3527.	0.6	1
98	Real-World Outcomes of Aggressive B-Cell Non-Hodgkin Lymphoma in People Living with HIV (PLWH) Treated in Australia: An Australasian Lymphoma Alliance Study. <i>Blood</i> , 2021, 138, 1456-1456.	0.6	1
99	Early Integration of High Dose Methotrexate to Frontline DLBCL Therapy Does Not Impact CNS Relapse Compared to End of Treatment Delivery: A Multicentre International Analysis of 1384 Patients. <i>Blood</i> , 2021, 138, 452-452.	0.6	1
100	Abstract CT138: Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in combination with venetoclax ± rituximab in relapsed/refractory chronic lymphocytic leukemia: Results from the BRUIN phase 1b study. <i>Cancer Research</i> , 2022, 82, CT138-CT138.	0.4	1
101	All is not lost - the improving outcome of patients with chronic lymphocytic leukaemia failing frontline therapy with fludarabine, cyclophosphamide and rituximab. <i>European Journal of Haematology</i> , 2013, 91, 189-190.	1.1	0
102	Is there still a need for specific central nervous system directed prophylaxis for diffuse large B-cell lymphoma in the rituximab era?. <i>Leukemia and Lymphoma</i> , 2014, 55, 471-473.	0.6	0
103	Three different hematologists, three different answers: how should we treat concurrent systemic and central nervous system lymphoma?. <i>Leukemia and Lymphoma</i> , 2017, 58, 2021-2023.	0.6	0
104	Questioning the value of routine imaging for patients with mantle cell lymphoma in first remission. <i>Leukemia and Lymphoma</i> , 2018, 59, 775-777.	0.6	0
105	Author reply. <i>Internal Medicine Journal</i> , 2019, 49, 1338-1339.	0.5	0
106	Management of patients with follicular lymphoma treated first line with obinutuzumab. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2019, 15, 3-11.	0.7	0
107	Designing optimal prognostic models for diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2019, 60, 1848-1850.	0.6	0
108	Event free survival at 12 months (EFS12) in stage 1 DLBCL – a reassuring milestone?. <i>Leukemia and Lymphoma</i> , 2020, 61, 2542-2543.	0.6	0

#	ARTICLE	IF	CITATIONS
109	Mantle cell lymphoma â€” where precision medicine based on responseâ€”adapted treatment strategies could show its full worth. <i>British Journal of Haematology</i> , 2020, 189, 600-602.	1.2	0
110	Routine imaging for disease surveillance in follicular lymphomaâ€”To comfort the patients or their doctors?. <i>Cancer</i> , 2021, 127, 3298-3301.	2.0	0
111	Impact of Induction Chemotherapy and Primary CNS Prophylaxis on Outcomes in High-Grade B-Cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements (HGDL-DH/TH) or HGDL-NOS: An International Multi-Center Retrospective Analysis. <i>Blood</i> , 2018, 132, 4224-4224.	0.6	0
112	Management and Outcomes of Diffuse Large B Cell Lymphoma Post-Transplant Lymphoproliferative Disorder in the PET/CT Era: A Multicentre Study from the Australasian Lymphoma Alliance. <i>Blood</i> , 2020, 136, 36-38.	0.6	0
113	The Burkitt Lymphoma International Prognostic Index (BL-IPI). <i>Blood</i> , 2020, 136, 46-49.	0.6	0